Development of small diameter nanofiber tissue engineered arterial grafts.
The surgical repair of heart and vascular disease often requires implanting synthetic grafts. While synthetic grafts have been successfully used for medium-to-large sized arteries, applications for small diameter arteries (<6 mm) is limited due to high rates of occlusion by thrombosis. Our object...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0120328 |
| _version_ | 1818826295292723200 |
|---|---|
| author | Hirotsugu Kurobe Mark W Maxfield Shuhei Tara Kevin A Rocco Paul S Bagi Tai Yi Brooks Udelsman Zhen W Zhuang Muriel Cleary Yasuko Iwakiri Christopher K Breuer Toshiharu Shinoka |
| author_facet | Hirotsugu Kurobe Mark W Maxfield Shuhei Tara Kevin A Rocco Paul S Bagi Tai Yi Brooks Udelsman Zhen W Zhuang Muriel Cleary Yasuko Iwakiri Christopher K Breuer Toshiharu Shinoka |
| author_sort | Hirotsugu Kurobe |
| collection | DOAJ |
| description | The surgical repair of heart and vascular disease often requires implanting synthetic grafts. While synthetic grafts have been successfully used for medium-to-large sized arteries, applications for small diameter arteries (<6 mm) is limited due to high rates of occlusion by thrombosis. Our objective was to develop a tissue engineered vascular graft (TEVG) for small diameter arteries. TEVGs composed of polylactic acid nanofibers with inner luminal diameter between 0.5 and 0.6 mm were surgically implanted as infra-renal aortic interposition conduits in 25 female C17SCID/bg mice. Twelve mice were given sham operations. Survival of mice with TEVG grafts was 91.6% at 12 months post-implantation (sham group: 83.3%). No instances of graft stenosis or aneurysmal dilatation were observed over 12 months post-implantation, assessed by Doppler ultrasound and microCT. Histologic analysis of explanted TEVG grafts showed presence of CD31-positive endothelial monolayer and F4/80-positive macrophages after 4, 8, and 12 months in vivo. Cells positive for α-smooth muscle actin were observed within TEVG, demonstrating presence of smooth muscle cells (SMCs). Neo-extracellular matrix consisting mostly of collagen types I and III were observed at 12 months post-implantation. PCR analysis supports histological observations. TEVG group showed significant increases in expressions of SMC marker, collagen-I and III, matrix metalloproteinases-2 and 9, and itgam (a macrophage marker), when compared to sham group. Overall, patency rates were excellent at 12 months after implantation, as structural integrity of these TEVG. Tissue analysis also demonstrated vessel remodeling by autologous cell. |
| first_indexed | 2024-12-19T00:25:23Z |
| format | Article |
| id | doaj.art-a7fd93a9bf6a4c17a3246975ae2f285c |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-19T00:25:23Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-a7fd93a9bf6a4c17a3246975ae2f285c2022-12-21T20:45:18ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01104e012032810.1371/journal.pone.0120328Development of small diameter nanofiber tissue engineered arterial grafts.Hirotsugu KurobeMark W MaxfieldShuhei TaraKevin A RoccoPaul S BagiTai YiBrooks UdelsmanZhen W ZhuangMuriel ClearyYasuko IwakiriChristopher K BreuerToshiharu ShinokaThe surgical repair of heart and vascular disease often requires implanting synthetic grafts. While synthetic grafts have been successfully used for medium-to-large sized arteries, applications for small diameter arteries (<6 mm) is limited due to high rates of occlusion by thrombosis. Our objective was to develop a tissue engineered vascular graft (TEVG) for small diameter arteries. TEVGs composed of polylactic acid nanofibers with inner luminal diameter between 0.5 and 0.6 mm were surgically implanted as infra-renal aortic interposition conduits in 25 female C17SCID/bg mice. Twelve mice were given sham operations. Survival of mice with TEVG grafts was 91.6% at 12 months post-implantation (sham group: 83.3%). No instances of graft stenosis or aneurysmal dilatation were observed over 12 months post-implantation, assessed by Doppler ultrasound and microCT. Histologic analysis of explanted TEVG grafts showed presence of CD31-positive endothelial monolayer and F4/80-positive macrophages after 4, 8, and 12 months in vivo. Cells positive for α-smooth muscle actin were observed within TEVG, demonstrating presence of smooth muscle cells (SMCs). Neo-extracellular matrix consisting mostly of collagen types I and III were observed at 12 months post-implantation. PCR analysis supports histological observations. TEVG group showed significant increases in expressions of SMC marker, collagen-I and III, matrix metalloproteinases-2 and 9, and itgam (a macrophage marker), when compared to sham group. Overall, patency rates were excellent at 12 months after implantation, as structural integrity of these TEVG. Tissue analysis also demonstrated vessel remodeling by autologous cell.https://doi.org/10.1371/journal.pone.0120328 |
| spellingShingle | Hirotsugu Kurobe Mark W Maxfield Shuhei Tara Kevin A Rocco Paul S Bagi Tai Yi Brooks Udelsman Zhen W Zhuang Muriel Cleary Yasuko Iwakiri Christopher K Breuer Toshiharu Shinoka Development of small diameter nanofiber tissue engineered arterial grafts. PLoS ONE |
| title | Development of small diameter nanofiber tissue engineered arterial grafts. |
| title_full | Development of small diameter nanofiber tissue engineered arterial grafts. |
| title_fullStr | Development of small diameter nanofiber tissue engineered arterial grafts. |
| title_full_unstemmed | Development of small diameter nanofiber tissue engineered arterial grafts. |
| title_short | Development of small diameter nanofiber tissue engineered arterial grafts. |
| title_sort | development of small diameter nanofiber tissue engineered arterial grafts |
| url | https://doi.org/10.1371/journal.pone.0120328 |
| work_keys_str_mv | AT hirotsugukurobe developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT markwmaxfield developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT shuheitara developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT kevinarocco developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT paulsbagi developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT taiyi developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT brooksudelsman developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT zhenwzhuang developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT murielcleary developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT yasukoiwakiri developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT christopherkbreuer developmentofsmalldiameternanofibertissueengineeredarterialgrafts AT toshiharushinoka developmentofsmalldiameternanofibertissueengineeredarterialgrafts |